Peeters A C, Netea M G, Kullberg B J, Thien T, van der Meer J W
Department of Medicine, University Hospital Nijmegen, The Netherlands.
Immunology. 1998 Jul;94(3):376-9. doi: 10.1046/j.1365-2567.1998.00524.x.
The balance between pro- and anti-inflammatory cytokines has been implicated in the pathogenesis of infectious and auto-immune diseases, and its modulation has been proposed as a potential therapeutic target. The results reported in the present study show that modulators of the renin-angiotensin system, such as the angiotensin-converting enzyme (ACE)-inhibitor captopril and the angiotensin II receptor type I antagonist valsartan, have potent inhibitory effects on the lipopolysaccharide (LPS)-stimulated production of pro-inflammatory cytokines tumour necrosis factor (TNF) and interleukin-1 (IL-1) in vitro. The anti-inflammatory cytokine IL-1Ra is increased by captopril, whereas IL-6 production is decreased by valsartan. These effects are exerted mainly at high concentrations of the drugs. Administration of one dose of captopril or valsartan in therapeutic dosages to patients with essential hypertension did not influence LPS-stimulated production of cytokines by whole blood. In conclusion, despite inhibitory effects on pro-inflammatory cytokine production in vitro, it is unlikely that captopril or valsartan could be used in anticytokine therapeutic strategies in vivo.
促炎细胞因子和抗炎细胞因子之间的平衡与感染性疾病和自身免疫性疾病的发病机制有关,调节这种平衡已被提议作为一个潜在的治疗靶点。本研究报告的结果表明,肾素-血管紧张素系统的调节剂,如血管紧张素转换酶(ACE)抑制剂卡托普利和血管紧张素II 1型受体拮抗剂缬沙坦,在体外对脂多糖(LPS)刺激的促炎细胞因子肿瘤坏死因子(TNF)和白细胞介素-1(IL-1)的产生具有强大的抑制作用。卡托普利可增加抗炎细胞因子IL-1Ra,而缬沙坦可降低IL-6的产生。这些作用主要在高浓度药物时发挥。对原发性高血压患者给予一剂治疗剂量的卡托普利或缬沙坦,并不影响LPS刺激全血产生细胞因子。总之,尽管卡托普利或缬沙坦在体外对促炎细胞因子的产生有抑制作用,但它们不太可能用于体内抗细胞因子治疗策略。